BiotechTube

JZP-110

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Excessive Sleepiness

Conditions

Excessive Sleepiness, Parkinson Disease

Trial Timeline

Jan 1, 2017 → Aug 1, 2018

NCT ID
NCT03037203

About JZP-110

JZP-110 is a phase 2 stage product being developed by Jazz Pharmaceuticals for Excessive Sleepiness. The current trial status is completed. This product is registered under clinical trial identifier NCT03037203. Target conditions include Excessive Sleepiness, Parkinson Disease.

What happened to similar drugs?

2 of 5 similar drugs in Excessive Sleepiness were approved

Approved (2) Terminated (1) Active (3)
✅Solriamfetol + PlaceboAxsome TherapeuticsApproved
🔄Solriamfetol 150 MG + PlaceboAxsome TherapeuticsPhase 3
🔄Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3
✅Solriamfetol Oral Tablet + PlaceboAxsome TherapeuticsApproved
🔄Fibrin Sealant Grifols + EVICELGrifolsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT03037203Phase 2Completed
NCT02348619Phase 3Completed
NCT02348632Phase 3Completed

Competing Products

8 competing products in Excessive Sleepiness

See all competitors
ProductCompanyStageHype Score
Placebo + PF-03654746PfizerPhase 2
35
Solriamfetol + PlaceboAxsome TherapeuticsApproved
40
Solriamfetol 150 MG + PlaceboAxsome TherapeuticsPhase 3
44
Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3
44
Solriamfetol Oral Tablet + PlaceboAxsome TherapeuticsApproved
32
Fibrin Sealant Grifols + EVICELGrifolsPhase 3
37
ORX142 TabletsCentessa PharmaceuticalsPhase 1
33
VSF-173Vanda PharmaceuticalsPhase 2
25